Stock Taper
SCREENER COMPARE ANY 2 STOCKS
OMER
OMEROS CORPORATION
NASDAQ
$18.61
▼ DOWN 3.32% (-0.64)

KEY STATISTICS

Market Cap$1.35 B
52w High$19.65
52w Low$3.94
Dividend Yield—
Frequency—
P/E8.54
Volume1.14M
Shares Out.72.38M

COMPANY

LEADERSHIP

Gregory A. Demopulos
CHIEF EXECUTIVE
Gregory A. Demopulos

COMPENSATION 2026

Salary$972,525
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$24,984
Total$4,178,008

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 8, 2009
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
175

PRICE TARGET

Target High$33.00
Target Low$33.00
Target Median$33.00
Target Consensus$33.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.$36.73M
NOV
12
THU

PRICE

$18.61 ▼ DOWN 3.32% (−$0.64)
$18.60$18.80$19.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM18.61

About Omeros Corporation

https://www.omeros.com ↗

Omeros Corporation is a biopharmaceutical company developing small-molecule and protein therapeutics targeting inflammation, immune-related diseases, cancers, and disorders, with multiple clinical and preclinical programs including Narsoplimab and...

INDUSTRY

Biotechnology

A PRODUCT OMEROS CORPORATION IS KNOWN FOR

Yartemlea (narsoplimab-wuug)
Yartemlea (narsoplimab-wuug)

Yartemlea, the first FDA-approved treatment for TA-TMA, is a monoclonal antibody inhibiting the lectin pathway of the complement system, establishing a new standard of care for this serious post-transplant complication.

COMPETITORS

COMPETITOR
AMGN COMPARE
AZN COMPARE
REGN COMPARE
SNY COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
101
LISTED HERE
17
RANKED BY POSITION SIZE
VTI
0.00% · 2.2M
XSU.TO
0.04% · 1.9M
XPH
2.68% · 817.6K
PBE
3.73% · 790.2K
SCHA
0.03% · 340.7K
BBP
2.71% · 167.6K
FSCC
0.48% · 90.9K
XRS2.DE
0.04% · 66.0K
RSSL
0.04% · 34.4K
ONEQ
0.01% · 33.7K
PILL
1.80% · 23.0K
JF
JFWD
4.11% · 19.9K
URTY
0.02% · 2.9K
KBFR
0.07% · 435
USFMDN.MX
0.00% · 341
AVUQ
0.00% · 236
RESM
0.06% · 200

INSTITUTIONAL OWNERSHIP

SHARES OWNED
46.98%
HOLDERS
245
TOP 12 OF 245 · RANKED BY POSITION SIZE
Blackrock, Inc.
6.0M sh · $57.48M
Ingalls & Snyder LLC
4.1M sh · $16.84M
Blackrock Inc.
4.1M sh · $16.65M
Vanguard Group Inc
4.0M sh · $68.93M
Ubs Group AG
3.1M sh · $29.94M
State Street Corp
2.3M sh · $22.06M
Morgan Stanley
2.0M sh · $8.16M
Blackrock Fund Advisors
1.9M sh · $19.11M
Geode Capital Management, LLC
1.9M sh · $18.21M
Stifel Financial Corp
1.8M sh · $17.47M
Polar Asset Management Partners Inc.
1.5M sh · $6.14M
Blackrock Institutional Trust Company, N.A.
1.1M sh · $10.94M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets5
Debt To Equity1
Price To Earnings3
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
HANISH ARNOLD C
Purchase · 7.5K shares
2026-08-27
★
DIRECTOR
HANISH ARNOLD C
Purchase · 5.0K shares
2026-08-26
★
DIRECTOR
HANISH ARNOLD C
Sale · 5.0K shares
2026-08-26
★
DIRECTOR
HANISH ARNOLD C
Purchase · 2.5K shares
2026-08-27

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
HOLD 1
STRONG BUY 1
4 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY D. Boral Capital BUY Needham HOLD WBB Securities STRONG BUY

SECTORS PEERS

PEERPRICE
LXRX$2.29COMPARE
FDMT$14.67COMPARE
OCGN$1.32COMPARE
FULC$3.85COMPARE
BCYC$4.20COMPARE
NMRA$1.39COMPARE
ADCT$1.14COMPARE
GOSS$0.17COMPARE